Rescuing neurons in prion disease

Biochemical Journal

Volumn 433, Issue 1, 2011, Pages 19-29

  Verity, Nicholas C ^a   Mallucci, Giovanna R ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Behaviour; Neurodegeneration; Neurophysiological analysis; Prion; RNA interference (RNAi); Synaptic dysfunction

Indexed keywords

AMYLOID BETA PROTEIN; ATAXIN 1; CRE RECOMBINASE; HUNTINGTIN; LENTIVIRUS VECTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PRION PROTEIN; SHORT HAIRPIN RNA; SUPEROXIDE DISMUTASE;

BEHAVIOR; CEREBELLUM; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DISEASE FREE SURVIVAL; EXCITATORY POSTSYNAPTIC POTENTIAL; GENE SILENCING; HIPPOCAMPUS; HUMAN; LONG TERM POTENTIATION; LONGEVITY; NERVE CELL; NEUROPHYSIOLOGY; NEUROPROTECTION; NEUROTOXICITY; PATHOGENESIS; PRION DISEASE; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; SURVIVAL; TRANSGENIC MOUSE;

ANIMALS; DISEASE-FREE SURVIVAL; MICE; NEURONS; NEUROPROTECTIVE AGENTS; PRION DISEASES; REMISSION INDUCTION; RNA INTERFERENCE;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 79551482894     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20101323     Document Type: Review

References (63)

1. Collinge, J. (2005) Molecular neurology of prion disease. J. Neurol. Neurosurg. Psychiatry 76, 906-919
2. Prusiner, S. B. (1991) Molecular biology of prion diseases. Science 252, 1515-1522
3. Collinge, J., Owen, F., Poulter, M., Leach, M., Crow, T. J., Rossor, M. N., Hardy, J., Mullan, M. J., Janota, I. and Lantos, P. L. (1990) Prion dementia without characteristic pathology. Lancet 336, 7-9
4. Hill, A. F., Joiner, S., Linehan, J., Desbruslais, M., Lantos, P. L. and Collinge, J. (2000) Species-barrier-independent prion replication in apparently resistant species. Proc. Natl. Acad. Sci. U.S.A. 97, 10248-10253
5. Hill, A. F. and Collinge, J. (2003) Subclinical prion infection. Trends Microbiol. 11, 578-584
6. Prusiner, S. B. (1992) Natural and experimental prion diseases of humans and animals. Curr. Opin. Neurobiol. 2, 638-647
7. Manetto, V., Medori, R., Cortelli, P., Montagna, P., Tinuper, P., Baruzzi, A., Rancurel, G., Hauw, J. J., Vanderhaeghen, J. J., Mailleux, P. et al. (1992) Fatal familial insomnia: clinical and pathologic study of five new cases. Neurology 42, 312-319
8. Collinge, J., Palmer, M. S., Sidle, K. C., Gowland, I., Medori, R., Ironside, J. and Lantos, P. (1995) Transmission of fatal familial insomnia to laboratory animals. Lancet 346, 569-570
9. Trevitt, C. R. and Collinge, J. (2006) A systematic review of prion therapeutics in experimental models. Brain 129, 2241-2265
10. Sailer, A., Bueler, H., Fischer, M., Aguzzi, A. and Weissmann, C. (1994) No propagation of prions in mice devoid of PrP. Cell 77, 967-968
11. Bueler, H., Aguzzi, A., Sailer, A., Greiner, R. A., Autenried, P., Aguet, M. and Weissmann, C. (1993) Mice devoid of PrP are resistant to scrapie. Cell 73, 1339-1347
12. Manson, J. C., Clarke, A. R., McBride, P. A., McConnell, I. and Hope, J. (1994) PrP gene dosage determines the timing but not the final intensity or distribution of lesions in scrapie pathology. Neurodegeneration 3, 331-340
13. Brandner, S., Isenmann, S., Raeber, A., Fischer, M., Sailer, A., Kobayashi, Y., Marino, S., Weissmann, C. and Aguzzi, A. (1996) Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 379, 339-343
14. Bueler, H., Fischer, M., Lang, Y., Bluethmann, H., Lipp, H. P., DeArmond, S. J., Prusiner, S. B., Aguet, M. and Weissmann, C. (1992) Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356, 577-582
15. + currents. Neurosci. Lett. 209, 49-52
16. Bremer, J., Baumann, F., Tiberi, C., Wessig, C., Fischer, H., Schwarz, P., Steele, A. D., Toyka, K. V., Nave, K. A., Weis, J. and Aguzzi, A. (2010) Axonal prion protein is required for peripheral myelin maintenance. Nat. Neurosci. 13, 310-318
17. Mallucci, G. R., Ratte, S., Asante, E. A., Linehan, J., Gowland, I., Jefferys, J. G. and Collinge, J. (2002) Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J. 21, 202-210 (Pubitemid 34137282)
18. Mallucci, G., Dickinson, A., Linehan, J., Klohn, P. C., Brandner, S. and Collinge, J. (2003) Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302, 871-874
19. Moser, M., Colello, R. J., Pott, U. and Oesch, B. (1995) Developmental expression of the prion protein gene in glial cells. Neuron 14, 509-517
20. Jeffrey, M., Goodsir, C. M., Bruce, M. E., McBride, P. A. and Fraser, J. R. (1997) In vivo toxicity of prion protein in murine scrapie: ultrastructural and immunogold studies. Neuropathol. Appl. Neurobiol. 23, 93-101
21. Clark, R. E., Zola, S. M. and Squire, L. R. (2000) Impaired recognition memory in rats after damage to the hippocampus. J. Neurosci. 20, 8853-8860
22. Gerlai, R. and Clayton, N. S. (1999) Analysing hippocampal function in transgenic mice: an ethological perspective. Trends Neurosci. 22, 47-51
23. Cunningham, C., Deacon, R. M., Chan, K., Boche, D., Rawlins, J. N. and Perry, V. H. (2005) Neuropathologically distinct prion strains give rise to similar temporal profiles of behavioral deficits. Neurobiol. Dis. 18, 258-269
24. Deacon, R. M., Raley, J. M., Perry, V. H. and Rawlins, J. N. (2001) Burrowing into prion disease. NeuroReport 12, 2053-2057
25. Guenther, K., Deacon, R. M., Perry, V. H. and Rawlins, J. N. (2001) Early behavioural changes in scrapie-affected mice and the influence of dapsone. Eur. J. Neurosci. 14, 401-409
26. Mallucci, G. R., White, M. D., Farmer, M., Dickinson, A., Khatun, H., Powell, A. D., Brandner, S., Jefferys, J. G. and Collinge, J. (2007) Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron 53, 325-335
27. Mucke, L., Masliah, E., Yu, G. Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K. and McConlogue, L. (2000) High-level neuronal expression of Aβ 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050-4058
28. Buttini, M., Yu, G. Q., Shockley, K., Huang, Y., Jones, B., Masliah, E., Mallory, M., Yeo, T., Longo, F. M. and Mucke, L. (2002) Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid β peptides but not on plaque formation. J. Neurosci. 22, 10539-10548
29. Wang, H. W., Pasternak, J. F., Kuo, H., Ristic, H., Lambert, M. P., Chromy, B., Viola, K. L., Klein, W. L., Stine, W. B., Krafft, G. A. and Trommer, B. L. (2002) Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924, 133-140
30. Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J. and Selkoe, D. J. (2002) Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539
31. Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L. et al. (1998) Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 95, 6448-6453
32. Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E. et al. (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481
33. Yamamoto, A., Lucas, J. J. and Hen, R. (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101, 57-66
34. Paul, C. P., Good, P. D., Winer, I. and Engelke, D. R. (2002) Effective expression of small interfering RNA in human cells. Nat. Biotechnol. 20, 505-508
35. Sui, G., Soohoo, C., Affar el, B., Gay, F., Shi, Y. and Forrester, W. C. (2002) A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 99, 5515-5520
36. Xia, H., Mao, Q., Eliason, S. L., Harper, S. Q., Martins, I. H., Orr, H. T., Paulson, H. L., Yang, L., Kotin, R. M. and Davidson, B. L. (2004) RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 10, 816-820
37. Harper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L. and Davidson, B. L. (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U.S.A. 102, 5820-5825
38. Raoul, C., Abbas-Terki, T., Bensadoun, J. C., Guillot, S., Haase, G., Szulc, J., Henderson, C. E. and Aebischer, P. (2005) Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med. 11, 423-428
39. Rodriguez-Lebron, E., Gouvion, C. M., Moore, S. A., Davidson, B. L. and Paulson, H. L. (2009) Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease. Mol. Ther. 17, 1563-1573
40. Rodriguez-Lebron, E., Denovan-Wright, E. M., Nash, K., Lewin, A. S. and Mandel, R. J. (2005) Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol. Ther. 12, 618-633
41. Ralph, G. S., Radcliffe, P. A., Day, D. M., Carthy, J. M., Leroux, M. A., Lee, D. C., Wong, L. F., Bilsland, L. G., Greensmith, L., Kingsman, S. M. et al. (2005) Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med. 11, 429-433
42. Sapru, M. K., Yates, J. W., Hogan, S., Jiang, L., Halter, J. and Bohn, M. C. (2006) Silencing of human α-synuclein in vitroand in rat brain using lentiviral-mediated RNAi. Exp. Neurol. 198, 382-390
43. Singer, O., Marr, R. A., Rockenstein, E., Crews, L., Coufal, N. G., Gage, F. H., Verma, I. M. and Masliah, E. (2005) Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat. Neurosci. 8, 1343-1349
44. Boudreau, R. L. and Davidson, B. L. (2010) RNAi therapeutics for CNS disorders. Brain Res. 1338, 112-121
45. White, M. D., Farmer, M., Mirabile, I., Brandner, S., Collinge, J. and Mallucci, G. R. (2008) Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc. Natl. Acad. Sci. U.S.A. 105, 10238-10243
46. Fischer, M., Rulicke, T., Raeber, A., Sailer, A., Moser, M., Oesch, B., Brandner, S., Aguzzi, A. and Weissmann, C. (1996) Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J. 15, 1255-1264
47. Bueler, H., Raeber, A., Sailer, A., Fischer, M., Aguzzi, A. and Weissmann, C. (1994) High prion and PrPSc levels but delayed onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP gene. Mol. Med. 1, 19-30
48. Boudreau, R. L., McBride, J. L., Martins, I., Shen, S., Xing, Y., Carter, B. J. and Davidson, B. L. (2009) Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol. Ther. 17, 1053-1063
49. Mazarakis, N. D., Azzouz, M., Rohll, J. B., Ellard, F. M., Wilkes, F. J., Olsen, A. L., Carter, E. E., Barber, R. D., Baban, D. F., Kingsman, S. M. et al. (2001) Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum. Mol. Genet. 10, 2109-2121
50. Kato, S., Inoue, K., Kobayashi, K., Yasoshima, Y., Miyachi, S., Inoue, S., Hanawa, H., Shimada, T. and Takada, M. (2007) Efficient gene transfer via retrograde transport in rodent and primate brains using a human immunodeficiency virus type 1-based vector pseudotyped with rabies virus glycoprotein. Hum. Gene Ther. 18, 1141-1151
51. Oh, S., Odland, R., Wilson, S. R., Kroeger, K. M., Liu, C., Lowenstein, P. R., Castro, M. G., Hall, W. A. and Ohlfest, J. R. (2007) Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J. Neurosurg. 107, 568-577
52. Hadaczek, P., Kohutnicka, M., Krauze, M. T., Bringas, J., Pivirotto, P., Cunningham, J. and Bankiewicz, K. (2006) Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum. Gene Ther. 17, 291-302
53. Sanftner, L. M., Sommer, J. M., Suzuki, B. M., Smith, P. H., Vijay, S., Vargas, J. A., Forsayeth, J. R., Cunningham, J., Bankiewicz, K. S., Kao, H. et al. (2005) AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters. Exp. Neurol. 194, 476-483
54. Braak, H. and Braak, E. (1995) Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 16, 271-278
55. Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M. et al. (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11, 909-913
56. Goedert, M., Clavaguera, F. and Tolnay, M. (2010) The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci. 33, 317-325
57. Khosravani, H., Zhang, Y., Tsutsui, S., Hameed, S., Altier, C., Hamid, J., Chen, L., Villemaire, M., Ali, Z., Jirik, F. R. and Zamponi, G. W. (2008) Prion protein attenuates excitotoxicity by inhibiting NMDA receptors. J. Gen. Physiol. 131, i5
58. Lauren, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W. and Strittmatter, S. M. (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature 457, 1128-1132
59. Calella, A. M., Farinelli, M., Nuvolone, M., Mirante, O., Moos, R., Falsig, J., Mansuy, I. M. and Aguzzi, A. (2010) Prion protein and Aβ-related synaptic toxicity impairment. EMBO Mol. Med. 2, 306-314
60. Balducci, C., Beeg, M., Stravalaci, M., Bastone, A., Sclip, A., Biasini, E., Tapella, L., Colombo, L., Manzoni, C., Borsello, T. et al. (2010) Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein. Proc. Natl. Acad. Sci. U.S.A. 107, 2295-2300
61. Gimbel, D. A., Nygaard, H. B., Coffey, E. E., Gunther, E. C., Lauren, J., Gimbel, Z. A. and Strittmatter, S. M. (2010) Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J. Neurosci. 30, 6367-6374
62. Kessels, H. W., Nguyen, L. N., Nabavi, S. and Malinow, R. (2010) The prion protein as a receptor for amyloid-β. Nature 466, E3-E4
63. Asante, E. A., Linehan, J. M., Desbruslais, M., Joiner, S., Gowland, I., Wood, A. L., Welch, J., Hill, A. F., Lloyd, S. E., Wadsworth, J. D. and Collinge, J. (2002) BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO J. 21, 6358-6366